Longitudinally Extensive Transverse Myelitis in a Patient with Psoriatic Arthritis: A Therapeutic Dilemma with Clinical Response to Dimethyl Fumarate
Year: 2026
Type: preprint
Study design: Case Report
Abstract: Background Longitudinally extensive transverse myelitis (LETM) is a severe inflammatory myelopathy defined by a T2-hyperintense spinal cord lesion extending across three or more contiguous vertebral segments. Although strongly associated with AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) and also seen in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), LETM may occur in other autoimmune settings and, rarely, during immune-modulating therapy. Coexisting PsA creates a therapeutic challenge because neurological treatment may worsen psoriatic disease. Case presentation: A 32-year-old man with a 17-year history of PsA, previously controlled with adalimumab, developed progressive paraparesis, a T4/T5 sensory level, paresthesia, constipation, and urinary retention. Approximately a year before presentation, paresthesia and mild left-leg weakness began following an episode of herpes zoster (shingles), with substantial neurological deterioration during the four weeks before referral. Spinal MRI showed a continuous T2–T4 intramedullary lesion. Brain MRI was normal; AQP4-IgG, MOG-IgG, and systemic autoimmune serologies were negative, while CSF showed mild lymphocytic pleocytosis and elevated protein without CSF-restricted oligoclonal bands. Adalimumab was discontinued because of concern for TNF-inhibitor-associated CNS demyelination. After intravenous methylprednisolone, rituximab was started for relapse prevention but was stopped after severe psoriasis involving > 20% of body surface area developed within 12 weeks. Dimethyl fumarate (DMF) was then initiated at 120 mg twice daily for 1 week, followed by 240 mg twice daily. During 2 years of follow-up, neurological function and bladder control improved, psoriasis achieved clinical remission, and MRI demonstrated marked regression of the spinal cord lesion, with no new CNS lesions. Conclusion This case highlights the therapeutic complexity of seronegative LETM in a patient with PsA and prior anti-TNF exposure. The temporal association with adalimumab raises, but does not establish, a drug-related mechanism. DMF offered a pragmatic single-agent strategy because of its established activity in demyelinating disorders such as multiple sclerosis, and plaque psoriasis; however, it is not an established maintenance treatment for idiopathic LETM or NMOSD, and this single favorable outcome cannot establish neurological efficacy. The main value of this report lies in the clinical experience it provides and in illustrating the multidisciplinary decision-making required when neuroinflammatory and psoriatic diseases coexist.
Source: Research Square
Institution: Isfahan University of Medical Sciences
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7235454461
